
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI is a promising company due to its reaffirmed outlook, long-term growth targets, recent note offering, unique AI approach, undervaluation, FDA approval for a new product, potential in data licensing and model development, reinvestment plans, and potential growth in rare diseases and digital AI products. With a target of $75, the company's potential for growth and improved cash generation was further highlighted at the recent Analyst Day.
Bears say
Tempus AI is facing intense competition in the healthcare and artificial intelligence sectors, which poses significant risks to its ability to sustain growth. Its dependency on continuous growth in the Tempus dataset also leaves the company vulnerable to potential loss of market share in the genomic testing market or loss of health system customers. Furthermore, the company's expansion plans in MRD and rare disease bring high expectations, but the volatility of ordering patterns and funding from the U.S. Department of Veterans Affairs could hinder their success.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares